Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall …

E Grande, JÁ Arranz, M De Santis, A Bamias… - The Lancet …, 2024 - thelancet.com
Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …
被引用次数：17 相关文章

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall …

E Grande, JÁ Arranz, M De Santis… - The Lancet …, 2024 - pubmed.ncbi.nlm.nih.gov
Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall …

E Grande, JÁ Arranz, M De Santis, A Bamias… - The Lancet …, 2024 - Elsevier
Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

[引用][C] Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall …

E Grande, JÁ Arranz, M De Santis… - The Lancet …, 2024 - produccioncientifica.ucm.es
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally
advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results …